OncLive | Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2 OncLive New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups. The data were presented at the 2013 ... |
